Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. Its lead program, PLN-101095, is an oral small-molecule dual-selective inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including immune checkpoint inhibitor-refractory advanced or metastatic disease.
Company updates commonly cover Phase 1 and Phase 1b oncology data, scientific-conference presentations, combination studies with pembrolizumab, financial results, and healthcare investor-conference participation. Pliant also describes preclinical platform work using integrin receptor-binding molecules for tissue-specific delivery and internalization of drug payloads, including programs directed to skeletal muscle cells, adipocytes, and renal cells.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology firm, announced participation in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 3:45 p.m. ET. Bernard Coulie, M.D., Ph.D., President and CEO, and Éric Lefebvre, M.D., Chief Medical Officer, will engage in a fireside chat accessible via their Investor Relations page. Pliant's lead product, bexotegrast, is focused on treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) and has received Fast Track and Orphan Drug Designations. They are also advancing programs for nonalcoholic steatohepatitis (NASH) and solid tumors, with ongoing Phase 2a trials.
Pliant Therapeutics (PLRX) announced it will present three scientific posters at the 2023 American Thoracic Society (ATS) International Conference from May 19-24, 2023, in Washington, DC. Highlights include data from the Phase 2a trial of bexotegrast (PLN-74809), a dual-selective integrin inhibitor being developed for idiopathic pulmonary fibrosis (IPF). Two of the presentations have been selected for featured oral presentations. The company emphasizes the drug's mechanism of action and its ongoing clinical development, which has received FDA Fast Track and Orphan Drug Designations.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) has received a positive recommendation from an independent Data Safety Monitoring Board (DSMB) to continue its INTEGRIS-PSC Phase 2a trial for bexotegrast, a dual-selective integrin inhibitor. The trial will now advance to a 320 mg dose group, enrolling patients for 24 to 48 weeks. Over 600 participants have been treated with no severe adverse events reported. The trial addresses the unmet medical need for primary sclerosing cholangitis (PSC), and interim results from initial dose groups are expected in Q3 2023. The company emphasizes the potential of bexotegrast and its commitment to developing therapies for fibrosis-related diseases.
Pliant Therapeutics (PLRX) announced positive interim data from its Phase 2a INTEGRIS-IPF trial for bexotegrast, showing a favorable safety profile and significant increases in forced vital capacity (FVC) at 12 weeks. The company completed a $287.5 million equity financing, extending its cash runway into 2026. Further data from the 320 mg dose group is expected in Q2 2023, along with initiation of a Phase 1 trial for PLN-101095 in solid tumors. Research and development expenses rose to $25.1 million, while net loss increased to $35.1 million in Q4 2022. As of December 31, 2022, PLRX had $331.2 million in cash and equivalents.